Replies to post #91442 on Innovation Pharmaceuticals Inc (IPIX)

[TheHound]

I don't think anyone here would argue that the disappearance of the lesion is only telling only part of the story. The rest is unknown to us at this time. Much is left to be known as the trial plays out. So what's ur point?

[Amatuer17]

I am no Dr but here is some reference material that i had posted before - maybe you already know it.

For me - this is more of investment call based on my judgement which is based on published information. In my view - elimination of lesion was much more positive factor than ca125. I am not ready to read too much more information is provided.


"On CA125 - some reference material - Gives very good description - has one section on false postive results

http://www.foundationforwomenscancer.org/wp-content/uploads/CA125levels.pdf

CA 125 is a substance found in the blood called a glycoprotein (a
sugar associated protein). It is commonly referred to as a “biomarker” —or “tumor marker” — because it provides information about the biologicalstate of a disease (ovarian cancer) and is obtained by a blood sample from
which a level can be measured. But it is more accurately considered a “tumorassociated protein” because elevated CA 125 levels do not always indicate ovarian cancer and levels can misrepresent a biological state.


So, the CA 125 test is helpful, but not perfect. Individual values are hard to interpret, so many physicians focus on the trend in the values over a course of time rather than any individual value. Time trends help to put the individual
values into perspective to get a “picture” of what might be going on in aparticular situation. "

[Astavakra]

p53. Interesting name choice for such an ambivalent onlooker. It does grab attention on this MB, though, so probably a good choice for your purposes.
If you haven't already, as part of your DD on CTIX, I'd suggest you listen to Dr. Alexander's presentation at the recent Biotech Showcase wherein he outlined the case of the spleen patient. You'll find it here:
http://cellceutix.com/wp-content/uploads/2014/06/CTIX-Biotech-Showcase-2015-AUDIO-1.mp3

Pay particular attention beginning around the 12 minute mark. At about 12:15 in, he opines that her disease was stable and that this is a case of 'treating the numbers and not the patient'. This is coming from a doctor with more information and familiarity with this case than any of us here. Of course, you may make of it what you will, but why not get as close to the source as possible before doing so?